Research Paper Volume 15, Issue 21 pp 12651—12673
Discovery and identification of the prognostic significance and potential mechanism of FMO2 in breast cancer
Figure 5. High FMO2 expression was sensitive to immunotherapy in PFS. (A) Anti-PD-1 immunotherapy. (B) Anti-PD-L1 immunotherapy. (C) Anti-CTLA-4 immunotherapy. (D) Pembrolizumab immunotherapy. (E) Nivolumab immunotherapy. (F) Atezolizumab immunotherapy. (G) Durvalumab immunotherapy. (H) Ipilimumab immunotherapy.